The $10 billion business of perimenopause

A slew of new companies is finally addressing the estimated 6,000 women a day who enter perimenopause. What took so long?

Around the time Emily Barclay turned 39, she was suddenly besieged by fatigue. Her stomach bloated after simple meals. Her memory faded. For three-and-a-half years, she saw doctors, trying to discern the source of her strange array of symptoms, feeling that something was so fundamentally wrong, so fundamentally different.

Read Full Story

Related Articles

Can AI read your emotions? Try it for yourself

Emotion recognition AI is bunk. Don’t get me wrong, AI that recognizes human sentiment and emotion can be very useful. For example, it can help identify when drivers are falling asleep behind the wheel. But what it cannot do, is discern how a human being is actually feeling by the expression on their face. You don’t have to take my word for it, you can try it yourself here. Dovetail Labs, a scientific research and consultancy company, recently created a website that explains how modern “emotion recognition” systems built on deep learning work. Typically when companies do stuff like this,… This story continues at The Next Web

Looking to launch a side hustle? Finally start with this accelerator course

TLDR: The Kim Perell’s Side Hustle Accelerator Course can get anyone started on launching and growing a lucrative side income business. While every path to success is different, taking that first step is invariably the toughest one. Deciding to start a new business, laying out a plan, and plunging ahead with those first formative decisions are always shrouded in uncertainty, indecision and, fundamentally, a certain level of fear. Of course, the best way to harness those fears is to step forward in the company of someone who’s walked that path before and can help guide you over some of the… This story continues at The Next Web

A startup that's taking on Big Pharma just raised $500 million

Summary List PlacementHello, 
Today in healthcare news: EQRx has raised another $500 million, at least 50% of COVID-19 cases spread from people without symptoms, and some evidence that Pfizer’s vaccine works against virus mutations. 

EQRx, a startup that’s taking on Big Pharma by making drugs cheaper, just raised $500 million

EQRx, a company developing new drugs that’ll compete with some of the highest-priced drugs on the market at a lower price, is moving faster than it expected.
A year in, the startup just raised a fresh $500 million from investors including GV, Andreessen Horowitz, and Arch Venture Partners, as well as from private equity funds, health plans and health systems.
It aims to get have its first treatment approved in the next “handful of years” and has brought on four cancer drugs that are in later stages of development. 

Read the full story here > >

At least 50% of COVID-19 cases spread from people without symptoms, a new study found

At least 50% of new COVID-19 cases are transmitted by people who don’t show symptoms, according to a new study.
That includes people who never display symptoms and those whose symptoms hadn’t started yet.
A study authors said findings underscore the need for people who feel healthy to follow public-health guidance on mask wearing and social distancing.

Read the full story from Susie Neilson here > >

Early study suggests Pfizer’s vaccine is effective against coronavirus mutations

A study by Pfizer and researchers at the University of Texas Medical Branch indicates the company’s COVID-19 vaccine is effective against mutations of the coronavirus.
The study has not yet been peer-reviewed.
“So we’ve now tested 16 different mutations, and none of them have really had any significant impact. That’s the good news,” Phil Dormitzer, a scientist at Pfizer, said Thursday. “That doesn’t mean that the 17th won’t,” he added.

Read the full story from Charles Davis here > >

More stories we’re reading: 

How West Virginia is winning the race to get COVID-19 vaccines into people’s arms, including using its own pharmacies (NPR)
Biden plans to release the entire coronavirus vaccine supply instead of reserving half to guarantee second doses (Business Insider)
LA is facing its “New York Moment” as the virus overwhelms the largest county in the US (The New York Times)
I felt totally fine after my first COVID-19 shot, but the second dose was rough. Here’s what I did to manage the side effects and why I still think you should get the shot. (Business Insider)

– LydiaJoin the conversation about this story » NOW WATCH: A cardiologist revealed the truth behind red wine’s health benefits

These are the 3 skills you need to succeed in 2021

If you’re looking to advance your career this year, the executive director of Harvard Business School Online suggests you hone your skills in these key areas.
In the past ten months, the world has been turned upside down. The uncertainty brought on by COVID has left many concerned about how their own skills align with a fundamentally changed economic landscape. Top jobs at organizations positioned to grow post-pandemic have more competition than ever. It’s therefore essential that you consider investing the time and money to acquire critical skills if you are looking to remain in your current role or secure a new one.Read Full Story

Responses

Your email address will not be published. Required fields are marked *

Receive the latest news

Subscribe To Our Weekly Newsletter

Get notified about chronicles from TreatMyBrand directly in your inbox